Related Experiment Video
Updated: Jun 15, 2026
07:35
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling
Philippe Jacqmin1, Lynn McFadyen, Janet R Wade
1Exprimo NV, Zwaanstraatje 4, 2800, Mechelen, Belgium. philippe.jacqmin@exprimo.com
Journal of Pharmacokinetics and Pharmacodynamics
|March 6, 2010
Summary
Disease progression modeling uses the Reproduction Minimum Inhibitory Concentration (RMIC) to predict treatment success. Achieving drug concentrations above the RMIC ensures system eradication and successful outcomes in proliferative and circular systems.
Area of Science:
- Pharmacology and Disease Modeling
- Mathematical Biology
- Pharmacokinetics/Pharmacodynamics (PK/PD)
Background:
- Disease progression modeling aids in understanding treatment effects over time.
- Proliferative and circular systems present complex dynamics for modeling.
- Predicting clinical outcomes requires understanding drug interactions within these systems.
Purpose of the Study:
- To introduce the Reproduction Minimum Inhibitory Concentration (RMIC) as a critical parameter for disease progression modeling.
- To establish a framework for defining dosing regimens in complex proliferative and circular systems.
- To predict the efficacy of pharmacological interventions based on PK/PD principles.
Main Methods:
- Derivation of the RMIC parameter, dependent on the basic reproductive ratio (R(0)) and IC(50).
- Calculation of equivalent effective constant concentration (ECC) to account for time-varying drug inhibition.
- Simulation of various dosing scenarios to assess treatment outcomes.
Main Results:
- RMIC represents the critical drug concentration for system extinction.
- Treatment success is predicted when drug exposure exceeds RMIC or ECC.
- Equivalent dosing regimens can be predicted based on IC(50) and PK parameters.
Conclusions:
- RMIC is a key determinant for successful eradication of proliferative and circular systems.
- ECC provides a method to manage time-varying drug concentrations for outcome prediction.
- Treatment success is primarily influenced by drug pharmacokinetics and dosing schedules.
Related Concept Videos
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:14Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A higher...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...